Inovio Pharmaceuticals (FRA:GBM) Research & Development: €44.88 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GBM Inovio Pharmaceuticals Inc FRA:GBM
43 GF Score
Price €1.02
GF Value €0.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Research & Development?

Inovio Pharmaceuticals FRA:GBM -3.24% 43 Research & Development is €44.88 Mil as of Mar. 2026. GuruFocus rates FRA:GBM with a GF Score™ of 43/100 and a GF Value™ of €0.19 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Inovio Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was €12.17 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €44.88 Mil.

Inovio Pharmaceuticals  (FRA:GBM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Inovio Pharmaceuticals Research & Development Related Terms

Inovio Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Research & Development Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 220.58 177.14 79.48 72.22 46.29

Inovio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.88 12.59 11.36 8.76 12.17
FRA:GBM
43GF Score
Inovio Pharmaceuticals Inc FRA:GBM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €44.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €44.88 Mil mean?
Inovio Pharmaceuticals (FRA:GBM) has a Research & Development of €44.88 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Research & Development too high?
Inovio Pharmaceuticals' current Research & Development is €44.88 Mil. Overall, Inovio Pharmaceuticals has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Research & Development compare to NRXS and FBIO?
Inovio Pharmaceuticals' Research & Development of €44.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Research & Development is €44.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (FRA:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €1.02 — trading 434.2% above its estimated fair value. The current Research & Development is €44.88 Mil. Inovio Pharmaceuticals' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Inovio Pharmaceuticals (FRA:GBM), the current Research & Development is €44.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (FRA:GBM) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of €1.02 is trading 434.2% above its estimated GF Value™ of €0.19. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:GBM:

  • Research & Development: €44.88 Mil
  • GF Value™: €0.19 vs. price of €1.02 (434.2% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the FRA:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inovio Pharmaceuticals Business Description

Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
43GF Score

Get the complete analysis for FRA:GBM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.02
Price
€0.19
GF Value